• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].

作者信息

Kornhuber M E, Zierz S

出版信息

Nervenarzt. 2003 Jun;74(6):537-8; discussion 539. doi: 10.1007/s00115-003-1523-4. Epub 2003 May 14.

DOI:10.1007/s00115-003-1523-4
PMID:12799792
Abstract
摘要

相似文献

1
[Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].[多发性硬化症免疫治疗的可能性与局限性。该疾病的炎症和退行性方面需要一个新的发病机制概念]
Nervenarzt. 2003 Jun;74(6):537-8; discussion 539. doi: 10.1007/s00115-003-1523-4. Epub 2003 May 14.
2
Newer long-term treatments for multiple sclerosis.多发性硬化症的新型长期治疗方法。
Clin Neurol Neurosurg. 2002 Jul;104(3):265-71. doi: 10.1016/s0303-8467(02)00050-1.
3
To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.治疗还是不治疗：特发性单症状脱髓鞘综合征的治疗困境
Arch Neurol. 2000 Jul;57(7):930-2. doi: 10.1001/archneur.57.7.930.
4
[Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
Vestn Ross Akad Med Nauk. 2001(7):18-22.
5
[Multiple sclerosis (MS), an inflammatory or degenerative disease?].
Presse Med. 2004 Feb 14;33(3):151-2. doi: 10.1016/s0755-4982(04)98510-7.
6
Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.关于舒海巴尔等人的评论：免疫调节剂疗法对多发性硬化症骨密度的有利影响。
Ir J Med Sci. 2009 Jun;178(2):235-6; author reply 237-8. doi: 10.1007/s11845-009-0275-y. Epub 2009 Jan 31.
7
[Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].[多发性硬化症患者使用疾病修饰药物治疗的副作用：对雅罗斯拉夫尔地区登记数据的分析]
Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(8):27-33.
8
[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Spec No 3:111-5.
9
[Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].β-干扰素和考帕松++在多发性硬化症治疗中的应用问题与前景
Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(4):33-6.
10
[Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].[巴西多发性硬化症治疗与研究委员会关于免疫调节药物在多发性硬化症中应用的建议：BCTRIMS 共识]
Arq Neuropsiquiatr. 2000 Sep;58(3A):769-76. doi: 10.1590/s0004-282x2000000400030.

引用本文的文献

1
[Noninflammatory pathogenesis of lesions in multiple sclerosis].[多发性硬化症病变的非炎症性发病机制]
Nervenarzt. 2006 Aug;77(8):989-90; author reply 990-2. doi: 10.1007/s00115-006-2120-0.

本文引用的文献

1
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].[多发性硬化症的免疫调节分阶段治疗。新进展与实际应用，2002年3月]
Nervenarzt. 2002 Jun;73(6):556-63. doi: 10.1007/s00115-002-1328-x.
2
Focal encephalitis in the Lewis rat induced by intracerebral enterotoxin superantigen and amplified by activated intravenous splenocytes.脑内肠毒素超抗原诱导并经活化的静脉注射脾细胞扩增的Lewis大鼠局灶性脑炎。
Neurosci Lett. 2002 May 17;324(2):93-6. doi: 10.1016/s0304-3940(02)00107-6.
3
Immunopathology of secondary-progressive multiple sclerosis.
继发进展型多发性硬化症的免疫病理学
Ann Neurol. 2001 Nov;50(5):646-57. doi: 10.1002/ana.1255.
4
[Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
Nervenarzt. 2001 Feb;72(2):150-7. doi: 10.1007/s001150050729.
5
Relapses and progression of disability in multiple sclerosis.多发性硬化症的复发与残疾进展
N Engl J Med. 2000 Nov 16;343(20):1430-8. doi: 10.1056/NEJM200011163432001.
6
[MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].[多发性硬化症治疗共识小组。多发性硬化症的免疫调节分期治疗]
Nervenarzt. 1999 Apr;70(4):371-86.
7
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.皮下注射干扰素β-1a预防复发型/缓解型多发性硬化症复发和残疾的随机双盲安慰剂对照研究。PRISMS（皮下注射干扰素β-1a预防多发性硬化症复发和残疾）研究组。
Lancet. 1998 Nov 7;352(9139):1498-504.
8
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.干扰素β-1b治疗继发进展型多发性硬化症的安慰剂对照多中心随机试验。继发进展型多发性硬化症干扰素β-1b欧洲研究组
Lancet. 1998 Nov 7;352(9139):1491-7.
9
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.干扰素β-1b对复发缓解型多发性硬化症有效。I. 一项多中心、随机、双盲、安慰剂对照试验的临床结果。IFNB多发性硬化症研究组。
Neurology. 1993 Apr;43(4):655-61. doi: 10.1212/wnl.43.4.655.
10
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.共聚物1降低复发率并改善复发缓解型多发性硬化症的残疾状况：一项III期多中心、双盲、安慰剂对照试验的结果。共聚物1多发性硬化症研究组。
Neurology. 1995 Jul;45(7):1268-76. doi: 10.1212/wnl.45.7.1268.